Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0001175 (AIDS)
 120,706 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Results of a 48-week phase II trial of efavirenz (SUSTIVA, formerly DMP 266) in combination with indinavir resulted in an average viral load reduction of 2.38 out of a possible 2.49 logs. A comparison group, receiving only indinavir for 48 weeks, had a 1.89 log average reduction out of a possible 2.42 logs. Efavirenz, produced by DuPont Merck, is a non-nucleoside reverse transcriptase inhibitor that is effective against many HIV variants and resistance also develops slowly. Data from another study on efavirenz will be reported at the Sixth European Conference on Clinical Aspects and Treatment of HIV Infection, October 11-15 in Hamburg, Germany. The additional number that is used to report viral load measurements is explained.
AIDS Treat News 1997 Sep 19
PMID:Efavirenz (SUSTIVA, formerly DMP-266) 48-week data announced. 1136 90

Promising drug trial results were presented in late-breaking sessions at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) conference. Abbott Laboratories described an ongoing trial in which 141 patients reported favorable results when using ritonavir (Norvir) in combination with saquinavir (Invirase). DMP-266 was also effective in combination with indinavir (Crixivan) in suppressing viral loads. DuPont Merck reported effective treatments when using DMP-266 with indinavir and nelfinavir. Another study showed that the soft gel formulation of saquinavir (Fortovase) has nearly ten times the drug exposure of the current hard gel formulation (Invirase). ACTG 320 confirms that a triple combination of indinavir with two nucleoside analogues significantly slows disease progression.
AIDS Alert 1997 Nov
PMID:Conference updates show promising drug data. 1136 69

A phase II multicenter trial is underway to test the effectiveness of three new antiretrovirals in patients who are failing combination protease inhibitor therapy. The study, organized by Glaxo Wellcome, is testing the effectiveness of a combination of 1592, 141W94, and efavirenz (Sustiva or DMP-266). Volunteers must be at least 13 years old, with viral loads over 500 following protease inhibitor therapy. Other criteria include no AIDS-defining opportunistic infections or malignancies except Kaposi's sarcoma. Each of the drugs has side effects associated with it, and rash has been the most common reason for each drug to be discontinued.
AIDS Treat News 1997 Dec 05
PMID:Protease inhibitor failure trial: combination 1592, 141W94, and efavirenz. 1136 14

Although there have been great strides in AIDS research, there is no major development on the horizon that is capturing the attention of the press. However, there are significant developments being made in a number of areas. Current antiretroviral treatments are leading to declines in AIDS deaths and infections in the United States and studies are leading to a greater understanding of treatment failures and the role of compliance and adherence. Three new antiretrovirals are available in expanded access programs: abacavir (1592), efavirenz (Sustiva, DMP-266), and adefovir dipivoxil (Preveon, bis-POM PMEA). New treatment approaches will deal with restoring immune function, using vaccines to prevent HIV and opportunistic infection, and developing more antiretrovirals to combat the disease. The role of managed care and providing treatment to the uninsured and underinsured are also issues to be addressed in the coming year.
AIDS Treat News 1998 Jan 09
PMID:1998 outlook: treatment; research; access. 1136 51

Merck Pharmaceuticals has relaxed the criteria for expanded access for efavirenz (Sustiva or DMP-266). Under the new guidelines, patients who have ever had a CD4 count below 400 can now participate; earlier guidelines limited the program to those with counts below 50 within the last 90 days. European entry criteria will change shortly. Efavirenz must be used in conjunction with another antiretroviral that the patient has not taken previously. The drug is not recommended for use as monotherapy, and patients who have failed on non-nucleoside reverse transcriptase inhibitors are less likely to benefit from Sustiva because of a common mutation. Contact information is given for enrolling in the program.
AIDS Treat News 1998 Jan 09
PMID:Efavirenz (Sustiva) expanded access now to 400 CD4. 1136 52

The AIDS Clinical Trial Group 382 is enrolling pediatric volunteers in a study of the safety and tolerability of DMP-266 (Sustiva) in combination with nelfinavir (Viracept). Children must be less than sixteen, and must be taking at least one nucleoside analogue. Telephone numbers are provided for interested volunteers.
 ...
PMID:Combination study for children. 1136 91

DuPont Merck opened an expanded access program for Sustiva (DMP 266). The program is open to AIDS patients with T-cell counts less than 50 who are failing other antiretroviral therapies. Little data exists on the safety of the drug and there are cross-resistance issues. Adefovir (Preveon) is available through Gilead's unlimited expanded access program for persons with T-cell counts below 50 and viral load greater than 30,000. Unlike Sustiva, an NNRTI, adefovir is a nucleotide analogue. Adefovir appears to be effective against several viruses; however, early reports suggest significant side effects, including kidney damage. Contact information is included for both programs.
 ...
PMID:Expanded access. 1136 7

DuPont Merck, manufacturer of the experimental drug efavirenz (Sustiva, DMP-266), has issued a warning to researchers and physicians concerning birth defects found in 3 of 13 monkey fetuses whose mothers took the drug throughout gestation. Researchers believe that the abnormalities manifested in the early stages of pregnancy. Human trials require participants to use birth control, but now strongly emphasize not becoming pregnant while taking the drug. Efavirenz has not demonstrated harm in late pregnancy and may be used in future trials to block maternal/fetal transmission of HIV.
AIDS Treat News 1998 Apr 03
PMID:Notice on efavirenz and pregnancy. 1136 85

Phase III data show that efavirenz (Sustiva, formerly DMP-266) is effective in suppressing viral load when used in combination with other treatments. A head-to-head comparison trial in volunteers with little or no previous antiretroviral experience shows that efavirenz may suppress viral load as well as Indinavir (Crixivan). Efavirenz is an experimental non-nucleoside reverse transcriptase inhibitor (NNRTI), and widespread consensus seems to accept it as a valid treatment for AIDS. The most noteworthy trial result showed that using it in combination with AZT plus 3TC suppressed viral load to below 400 copies in a significant number of volunteers, with few patients dropping out. Viral load remains low at 72 weeks, but not much information is available on those patients who were more heavily pre-treated. Other combinations also appear effective. DuPont Pharmaceuticals, the manufacturer, says common side effects include rash, nausea, diarrhea, headache, and insomnia, and cautions against widespread use in pregnant women. Efavirenz is unlikely to work in patients who have developed resistance to either Nevirapine or Delavirdine, two other NNRTI drugs.
AIDS Treat News 1998 Jul 17
PMID:Efavirenz (Sustiva) may equal or exceed protease inhibitor in initial antiretroviral combination. 1136 99

This first installment of a two-part article on new antiretroviral drugs in development provides information on seven new protease inhibitors (PIs). The results of in vitro and in vivo trials are provided. Researchers hope these drugs will be more potent and effective, have favorable resistance profiles, and be better tolerated by patients. Featured PIs include ABT 378, tipranavir, and DMP 450.
AIDS Clin Care 1999 May
PMID:New antiretroviral drugs part I: PIs. 1136 1


<< Previous 1 2 3 4 Next >>